All vaccines are expected to be quadrivalent. Included in the update are expanded approval for Flucelvax Quadrivalent, administration adjustments for Afluria Quadrivalent, and higher dose vaccines for those 65 years old and older.

Exploring the Korean National Health Insurance claims database revealed that rhythm control via ablation or drugs, initiated within 1 year of diagnosis of AF, was associated with lower risk for cardiovascular events. This held true for both low risk and higher risk patients. The study analyzed data on more than 35,000 patients with a median age of 70.

In a prospective study following the diet and activity records of more than 100,000 individuals in France, artificial sweeteners were positively correlated with cardiovascular diseases. Analyzing 900,000 person-years of data showed: Total artificial sweetener intake was associated with CVD risk Artificial sweeteners were more strongly associated with cerebrovascular disease Aspartame was associated with increase cerebrovascular events Acesulfame K and sucralose were associated with increased coronary heart disease risk

Over a 24-year-period, more than 200,000 men (n=46,341) and women (n=159,907) had dietary intake assessments performed every four years via survey. During the period, 3,216 CRC cancer cases were reported. Men with the highest 20% of ultra-processed food consumption had a 29% higher risk of developing colorectal cancer. For women, no association was seen between ultra-processed food consumption and risk of CRC. Ready-to-eat meat products and sugar-sweetened drinks among men and ready-to-eat/heat mixed dishes among women had the highest risk of CRC. Yogurt and dairy-based desserts had a negative associated risk for women.

With two cycles of neoadjuvant immunotherapy, nearly every patient with mismatch repair-deficient (dMMR) colon cancer in the NICHE-2 trial achieved a pathologic response. At a median follow-up of 13.1 months, the disease-free survival (DFS) rate was 100% vs. an expected rate for this patient population of 15%.

168 adults with unresectable stage IIIC-IV melanoma with progression after 1 line of systemic treatment (not including ipilimumab) were randomly assigned to receive tumor-infiltrating lymphocyte therapy or ipilimumab. With a median follow-up of nearly 3 years, the median PFS was 7.2 months in the TIL arm and 3.1 months in the ipilimumab arm.